Innovative Therapeutics Protego Bio is focused on developing first-in-class small molecule therapeutics targeting protein misfolding diseases, presenting opportunities to collaborate or supply complementary compounds for late-stage development or combination therapies.

Strong Funding Momentum With recent Series B funding of $130 million and earlier investments totaling $51 million, Protego Bio demonstrates significant financial backing, indicating readiness for expansion into clinical trials and potential partnerships for commercialization.

Clinical Pipeline Advancement The company's lead drug targeting amyloid light-chain amyloidosis is progressing into late-stage clinical testing, providing an entry point to offer clinical research services, diagnostics, or specialized formulation support.

Research Expertise Founded on pioneering work from the Scripps Research labs, Protego Bio has a strong research foundation, opening opportunities to supply research tools, biomolecular reagents, or partner on translational research initiatives.

Biotech Ecosystem Engagement As a company operating in the competitive biotechnology research sector with revenue between 1M and 10M, Protego Bio may benefit from strategic alliances in R&D, regulatory consulting, or technology licensing to accelerate product development.